UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal of Neural Transmission, ISSN 0300-9564, 2/2011, Volume 118, Issue 2, pp. 223 - 231
Desferrioxamine | Deferasirox | Brain iron | Neurology | Neurosciences | Medicine & Public Health | Iron chelators | Deferiprone | Pharmacology/Toxicology | Psychiatry | Parkinson’s disease | Parkinson's disease | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Immunohistochemistry | Triazoles - administration & dosage | Injections, Intraventricular | Rats | Male | Deferoxamine - administration & dosage | Rats, Sprague-Dawley | Benzoates - administration & dosage | Brain - drug effects | Pyridones - administration & dosage | Animals | Microdialysis | Sorbic Acid - administration & dosage | Free Radicals - analysis | Parkinsonian Disorders - drug therapy | Iron Chelating Agents - administration & dosage | Neuroprotective Agents - administration & dosage | Iron | Hydroxides | Neurons | Analysis | Index Medicus
Journal Article
Cancer cell, ISSN 1535-6108, 07/2015, Volume 28, Issue 1, pp. 57 - 69
Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Lung Neoplasms - drug therapy | Histone Demethylases - antagonists & inhibitors | Humans | Molecular Sequence Data | Lung Neoplasms - pathology | Antineoplastic Agents - administration & dosage | Histone Demethylases - genetics | Small Cell Lung Carcinoma - drug therapy | Enzyme Inhibitors - administration & dosage | Cyclopropanes - administration & dosage | Antineoplastic Agents - pharmacology | Epigenesis, Genetic - drug effects | Gene Expression Regulation, Neoplastic - drug effects | Cyclopropanes - pharmacology | Lung Neoplasms - genetics | Administration, Oral | Enzyme Inhibitors - pharmacology | Small Cell Lung Carcinoma - genetics | Benzoates - administration & dosage | Xenograft Model Antitumor Assays | Small Cell Lung Carcinoma - pathology | Animals | Benzoates - pharmacology | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | DNA Methylation - drug effects | Epigenetic inheritance | Lung cancer | DNA | Lysine | Index Medicus
Journal Article
Seminars in oncology, ISSN 0093-7754, 10/2011, Volume 38, Issue 5, pp. 635 - 647
Life Sciences & Biomedicine | Oncology | Science & Technology | Recombinant Proteins - therapeutic use | Benzoates - adverse effects | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Erythropoietin - therapeutic use | Recombinant Fusion Proteins - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Erythropoietin - adverse effects | Thrombopoietin - therapeutic use | Recombinant Proteins - adverse effects | Thrombopoietin - administration & dosage | Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use | Filgrastim | Patient Selection | Receptors, Fc - therapeutic use | Erythropoietin - analogs & derivatives | Drug-Related Side Effects and Adverse Reactions | Colony-Stimulating Factors - adverse effects | Epoetin Alfa | Hydrazines - administration & dosage | Myelodysplastic Syndromes - drug therapy | Recombinant Fusion Proteins - administration & dosage | Colony-Stimulating Factors - therapeutic use | Pyrazoles - adverse effects | Granulocyte Colony-Stimulating Factor - adverse effects | Erythropoietin - administration & dosage | Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage | Hydrazines - therapeutic use | Hematinics - therapeutic use | Polyethylene Glycols | Hematinics - adverse effects | Granulocyte Colony-Stimulating Factor - therapeutic use | Hematinics - administration & dosage | Recombinant Proteins - administration & dosage | Benzoates - administration & dosage | Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects | Pyrazoles - administration & dosage | Thrombopoietin - adverse effects | Receptors, Fc - administration & dosage | Darbepoetin alfa | Colony-Stimulating Factors - administration & dosage | Granulocyte Colony-Stimulating Factor - administration & dosage | Hydrazines - adverse effects
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 08/2018, Volume 320, Issue 6, pp. 566 - 579
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Benzoates - adverse effects | Sri Lanka | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Amlodipine - adverse effects | Hypertension - drug therapy | Male | Chlorthalidone - adverse effects | Benzoates - administration & dosage | Telmisartan | Dose-Response Relationship, Drug | Medication Adherence | Benzimidazoles - administration & dosage | Chlorthalidone - administration & dosage | Adult | Female | Potassium - blood | Aged | Blood Pressure - drug effects | Benzimidazoles - adverse effects | Amlodipine - administration & dosage | Drug Combinations | Hypertension | Control | Antihypertensive drugs | Dosage and administration | Blood pressure | Drug therapy | Health aspects | Drugs | Global health | Therapy | Kidneys | Medical treatment | Diabetes mellitus | Clinical trials | Patients | Blood | Pain | Syncope | Adults | Kidney diseases | Drug dosages | Mercury | Public health | Index Medicus | Abridged Index Medicus | Original Investigation | Research
Journal Article
Pediatric blood & cancer, ISSN 1545-5009, 12/2017, Volume 64, Issue 12, pp. e26657 - n/a
immune thrombocytopenic purpura | Promacta | eltrombopag | pediatric | Pediatrics | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Thrombocythemia, Essential - drug therapy | Hydrazines - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | United States | Humans | Child, Preschool | Infant | Male | Drug Approval | Benzoates - administration & dosage | Pyrazoles - administration & dosage | Adolescent | Female | Child | Chronic Disease | Hydrazines - administration & dosage | United States Food and Drug Administration | Thrombocytopenia | Children | Health aspects | Drug approval | Corticoids | Regulatory agencies | Immunoglobulins | Corticosteroids | Clinical trials | FDA approval | Patients | Splenectomy | Antidepressants | Risk assessment | Age | Index Medicus
Journal Article
Journal of controlled release, ISSN 0168-3659, 12/2014, Volume 196, pp. 154 - 160
Alveolar regeneration | Chronic obstructive pulmonary disease | Pulmonary administration | Am80 (Tamibarotene) | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Epithelial Cells - drug effects | Humans | Pulmonary Emphysema - pathology | Pulmonary Emphysema - drug therapy | Receptors, Retinoic Acid - metabolism | Pulmonary Disease, Chronic Obstructive - pathology | Benzoates - administration & dosage | Regeneration - drug effects | Animals | Tetrahydronaphthalenes - administration & dosage | Cell Differentiation - drug effects | Tetrahydronaphthalenes - pharmacology | Pulmonary Disease, Chronic Obstructive - chemically induced | Benzoates - pharmacology | Pancreatic Elastase | Pulmonary Alveoli - drug effects | Stem Cells - drug effects | Mice | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | DNA microarrays | Analysis | Stem cells | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 12, pp. 1238 - 1251
ACTIVE CONTROLLED-TRIALS | HIGH-RISK PATIENTS | TICLOPIDINE | TRANSIENT ISCHEMIC ATTACK | DOUBLE-BLIND | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | ARTERIAL ORIGIN ESPRIT | CEREBRAL-ISCHEMIA | UMCG Approved | NON-INFERIORITY TRIALS | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Neurology | Biological and medical sciences | General aspects | Vascular diseases and vascular malformations of the nervous system | Medical sciences | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Risk | Secondary Prevention | Aspirin - administration & dosage | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Ischemia - prevention & control | Factor Analysis, Statistical | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Stroke (Disease) | Aspirin | Usage | Care and treatment | Dipyridamole | Clopidogrel | Health aspects | Stroke | Index Medicus | Abridged Index Medicus | Recurrence | Brain Ischemia | Benzimidazoles | Follow-Up Studies | Neurons and Cognition | Cognition | Hemorrhage | Drug Delivery Systems | Life Sciences | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors | Vascular Diseases | Mental Status Schedule | Retrospective Studies | Severity of Illness Index | Disability Evaluation | Benzoates | Drug Administration Schedule | International Cooperation | Ticlopidine | Myocardial Infarction | Platelet Aggregation Inhibitors | Santé publique et épidémiologie | Original | Dipyridamole/adverse effects/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Recurrence/prevention & control | Benzoates/therapeutic use | Brain Ischemia/epidemiology/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Platelet Aggregation Inhibitors/administration & dosage/adverse | Combination | MEDICAL AND HEALTH SCIENCES | Aspirin/administration & dosage/adverse effects | Myocardial Infarction/epidemiology | Factor Analysis | Benzimidazoles/therapeutic use | Drug Therapy | Ticlopidine/adverse effects/analogs & derivatives/therapeutic use | effects/therapeutic use | Vascular Diseases/mortality | Hemorrhage/chemically induced | Stroke/drug therapy/epidemiology/prevention & control | Statistical | Kaplan-Meiers Estimate
Journal Article
American journal of respiratory and critical care medicine, ISSN 1073-449X, 12/2007, Volume 176, Issue 11, pp. 1138 - 1145
BAY 41-2272 | BAY 58-2667 | Pulmonary hypertension | BAY 41-8543 | Soluble guanylate cyclase | Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy | Pharmacology. Drug treatments | Biological and medical sciences | Intensive care medicine | Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases | Medical sciences | Respiratory system | Pneumology | Oxadiazoles - administration & dosage | Injections, Intravenous | Nitric Oxide - pharmacology | Purinones - administration & dosage | Dose-Response Relationship, Drug | Quinoxalines - pharmacology | Oxadiazoles - pharmacology | Lung - metabolism | Pyrazoles - pharmacology | Powders | Pyridines - administration & dosage | Quinoxalines - administration & dosage | Pyrimidines - administration & dosage | Morpholines - administration & dosage | Administration, Inhalation | Morpholines - pharmacology | Phosphodiesterase Inhibitors - pharmacology | Soluble Guanylyl Cyclase | Receptors, Cytoplasmic and Nuclear - agonists | Pyrimidines - pharmacology | Nitric Oxide - administration & dosage | Benzoates - administration & dosage | Particle Size | Phosphodiesterase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Animals | Cyclic GMP - metabolism | Guanylate Cyclase | Lung - drug effects | Aerosols | Benzoates - pharmacology | Purinones - pharmacology | Sheep | Pulmonary Circulation - drug effects | Pyridines - pharmacology | Vasodilation - drug effects | Drug Combinations | Index Medicus | Abridged Index Medicus | H. Pulmonary Vascular Disease | soluble guanylate cyclase | pulmonary hypertension
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2008, Volume 372, Issue 9638, pp. 547 - 553
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Benzoates - adverse effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Benzoates - therapeutic use | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Ramipril - administration & dosage | Proteinuria - chemically induced | Cardiovascular Diseases - complications | Glomerular Filtration Rate - drug effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Benzimidazoles - administration & dosage | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Ramipril - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | Ramipril - adverse effects | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Benzimidazoles - therapeutic use | Kidney - drug effects | Double-Blind Method | Diabetes Mellitus - drug therapy | Proteinuria - metabolism | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Creatinine - urine | Benzoates - administration & dosage | Creatinine - blood | Aged | Urine | Drugs | Studies | Kidneys | Disease | Clinical trials | Risk | ACE inhibitors | Index Medicus | Abridged Index Medicus
Journal Article